A cross-sectional study assessing the potential of the novel tau radiotracer 18-PI 2620 as a biomarker in patients with clinically diagnosed progressive supranuclear palsy
Latest Information Update: 17 Nov 2020
At a glance
- Drugs PI 2620 (Primary)
- Indications Progressive supranuclear palsy
- Focus Biomarker; Diagnostic use
- 17 Nov 2020 New trial record
- 01 Nov 2020 Results published in the JAMA Neurology